论文部分内容阅读
常用判断乳腺癌预后因素有:腋淋巴结转移及受侵数目、雌激素和孕激素受体的阳性率、原发肿瘤的大小以及诊断时的肿瘤病理分期.近期在人体乳腺癌可检出多种癌基因及其产物,但有关其与疾病结局的关系仍有争论.作者应用单克隆抗体cS93.1、9E1.0、F235-1.7.1和PAb1801针对所研究的癌基因蛋白,经抗生物素蛋白-生物素复合物免疫过氧化物方法作C-fos、C-myc、H-ras和p53结合癌基因蛋白的免疫组化染色,对85例乳腺癌 (1、ⅡA和ⅡB期)的病理组织进行了分析.40例(47%)已有癌肿复发,经随访48月(6～180月),余45例仍无转移迹象,作分子生物学测定,并与临床病理情况作相关性研究,以明确单一或多种癌基因并合表达的比例及其判断癌肿复发的价值.结果 癌基因表达的种类越多,癌肿的复发率越高,如一种基因表达为17.2%,二种表达为56.3%.三、四种表达则达100%(P=0.001).无癌基因表达者,无病生存23.4月,总生存期56.4月;而三种癌
Commonly used prognostic factors for breast cancer include axillary lymph node metastasis and invasion number, positive rate of estrogen and progesterone receptors, size of primary tumor, and pathological stage of the tumor at the time of diagnosis. Recently, many types of breast cancer can be detected. Oncogenes and their products, but there is still debate about their relationship with disease outcomes. The authors used monoclonal antibodies cS93.1, 9E1.0, F235-1.7.1, and PAb1801 against the oncogene protein under study, via the anti-biotin Protein-biotin complex immunoperoxidation method for immunohistochemical staining of C-fos, C-myc, H-ras, and p53-binding oncoproteins for the pathology of 85 cases of breast cancer (1, IIA, and IIB) The organization analyzed. Forty patients (47%) had cancer recurrence. After 48 months of follow-up (6 to 180 months), the remaining 45 patients still had no metastasis. They were used for molecular biological analysis and correlated with clinical pathological conditions. Study to clarify the proportion of single or multiple oncogenes combined expression and the value of judging cancer recurrence. Results The more types of oncogene expression, the higher the recurrence rate of cancer, such as a gene expression is 17.2%, two The expression was 56.3%. Three or four expressions were up to 100% (P=0.001). No expression of oncogenes, Disease-free survival 23.4 months, overall survival period 56.4 months; and three types of cancer